Gene-Therapy of Hepatitis С
Antiviral Genetic Programmes and Equipment for Gene-Therapy of Hepatitis С
Tech Area / Field
- BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
- MED-DRG/Drug Discovery/Medicine
3 Approved without Funding
Institute of Physical Chemical Medicine, Russia, Moscow
- State Enterprise Krasnaya Zvezda, Russia, Moscow
- The Carlyle Group, Russia, Moscow
Project summaryThe goal of the Project is to study the activity of the Antivirus Genetic Program (AGP), inducing specific cytotoxity of immune lymphocytes. To achieve this aim the protein spectrum of HCV-antigen and appreciating ability of AGP to block the forming of HCV virions will be studied.
The problem of the spread of infection caused by the hepatitis C virus (HCV) is now especially topical, as there are now 400 millions infected people in the world. In the USA alone 2% of the population suffer from this viral disease.
The most widespread method of treatment is the use of interferon, a non-specific inhibitor of replication of the virus. Most patients do not achieve a sustained remission with the first course of treatment. In 80% of cases the symptoms of the disease reappear. A repeat course of treatment is not effective. There is no specific therapy for hepatitis C.
The authors of the Project have worked out and experimentally confirmed the conception of AGP as a new type of DNA-vaccine. AGP is a highly specific antiviral preparation, a fact which is confirmed by the results of lab research. AGP is able to induce specific cytotoxity of immune lymphocytes. The conception of AGP is patented in the RF (Patent 2158139 and Patent 2159285). These patents have been awarded Gold Medal at the 2000 “Lipin” Patent Exhibition “Lipin” in Paris.
The following problems will be solved:
1. Determination of the protein composition of HCV-antigen in the cells with AGP upon the introduction of HCV of genomic RNA and a mixture of genomic RNA and antisense RNA of AGP.
2. Investigation of HCV-antigen, released from dead and living cells with the introduction of HCV of genomic RNA, by electronic microscope.
3. Investigation of HCV-antigen, released from dead and living cells with the introduction of HCV of genomic RNA and antisense RNA of AGP, by electronic microscope.
Expected results and their application
This research belongs to the field of Applied Research. The following data will be obtained as a result of the work:
a. Information about the functioning of the genetic program of the hepatitis C virus under the permanent presence of AGP in the cell;
b. Information about the ability of AGP to compete with the genetic program of the hepatitis C virus;
c. Information about the influence of AGP on forming HCV virions and the spread of infection in the cell culture.
d. Information about the possibility of recombination between AGP or antisense RNA of AGP and HCV of genomic RNA.
Experienced specialists in genetics, virology, biochemistry and molecular biology participate in this Project.
The project is deemed to be conversional and, thus, it is easy to predict its accomplishment. Project results will help to solve the problems connected with prophylaxis and treatment of hepatitis C
Project work is planned for 30 months. The key steps of the research are linked to the release and characterization of HCV-antigenes, and revealing the recombination between AGP and HCV of genomic RNA.
The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.
ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.